Application of tiliroside in preparation of medicine for treating atherosclerosis
By activating the PPARγ-LXRα-ABCA1/ABCG1 pathway, tilbene promotes cholesterol efflux and inhibits foam cell formation, solving the challenges of adverse reactions of statin drugs and atherosclerosis treatment, and achieving effective relief of atherosclerosis .
Patent Information
- Application Number
- CN202411266480.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-11
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing statins are used to treat atherosclerosis with severe adverse effects and lack of effective alternatives. Endothelial cell dysfunction in the early stages of atherosclerosis leads to foam cell formation, which in turn aggravates the progression of the disease.
The PPARγ-LXRα-ABCA1/ABCG1 pathway is used to activate the PPARγ-LXRα-ABCA1/ABCG1 pathway, promote cholesterol efflux, thereby inhibiting the formation of foam cells, and is prepared as a pharmaceutical preparation for oral or injection administration.
Silver tilbenes effectively reduces the formation of foam cells, reduces the levels of inflammatory factors, improves cholesterol metabolism, and reduces atherosclerotic plaques, providing a safe alternative treatment option.
Smart Images

Figure CN118903174A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of medicine, and in particular to the application of linaloside in the preparation of medicines for treating atherosclerosis. Background Art
[0002] Although the incidence and mortality of cardiovascular disease (CVD) have steadily declined over the past four decades, CVD remains a significant contributor to the global disease burden. Atherosclerosis (AS) is the most common underlying cause of CVD. Currently, statins are the mainstay of treatment for atherosclerosis. Despite their widespread use in clinical practice, increasing evidence suggests that long-term use of statins may lead to serious adverse effects, including liver damage, muscle toxicity, and gastrointestinal irritation. Therefore, there is an urgent need to develop alternative treatments for atherosclerosis.
[0003] The formation of foam cells is a hallmark of atherosclerosis. Accumulating evidence suggests that inhibiting the formation of foam cells is a promising strategy to prevent the progression of atherosclerotic lesions. The formation of foam cells depends on the balance of three interrelated biological processes: lipid uptake, cholesterol esterification, and cholesterol efflux. The regulation of these processes involves multiple transcription factors, including receptors, enzymes, and transporters. In the early stages of atherosclerosis, endothelial dysfunction leads to the transendothelial migration of low-density lipoprotein (LDL), which is subsequently modified into oxidized low-density lipoprotein (ox-LDL). Macrophages take up ox-LDL from the interior of the endothelium through scavenger receptors on their surface, such as CD36, LOX-1, and SR-A, ultimately leading to the formation of macrophage-derived foam cells. After being taken up by macrophages, ox-LDL is esterified and hydrolyzed into free cholesterol (FC) by enzymes such as ACAT-1 and NCEH1. Macrophages use membrane transporters including ABCA1, ABCG1, and SR-B1 to export cholesterol esters from the cell, thereby maintaining intracellular cholesterol homeostasis.
[0004] Argentin is a naturally occurring flavonoid found in a variety of plants that has attracted great interest in pharmacology and nutrition due to its promising role in regulating glucose and lipid metabolism. In addition, its anti-inflammatory properties make it a potential candidate for the treatment of chronic inflammation-related diseases. However, its application in the context of atherosclerosis has not been reported. Summary of the invention
[0005] In order to solve the above technical problems, the embodiments of the present invention provide the use of linaloside in the preparation of a drug for treating atherosclerosis.
[0006] To achieve the above object, the embodiments of the present invention adopt the following technical solutions:
[0007] In one aspect, the present invention provides the use of linaloside in the preparation of a drug for treating atherosclerosis.
[0008] In some embodiments, the structural formula of the linaloside is:
[0009]
[0010] In some embodiments, the daily dose of argyi tinctorius is 500 mg.
[0011] In some embodiments, the drug is administered by injection or orally.
[0012] In some embodiments, the drug comprises a pharmaceutical preparation prepared with an effective amount of linalool as an active ingredient and a pharmaceutically acceptable carrier and / or excipient.
[0013] The drug includes a pharmaceutical preparation prepared with an effective amount of linalool as an active ingredient and a pharmaceutically acceptable carrier and / or excipient. The effective amount refers to the amount of the drug, compound, or pharmaceutical composition necessary to obtain any one or more beneficial or desired therapeutic results. Beneficial or desired results include: clinical improvement (such as reducing morbidity, reducing mortality, improving one or more symptoms), reducing severity, delaying the onset of symptoms (including symptoms or their complications, intermediate pathological phenotypes presented during the development of the disease, biochemistry, histology, and / or behavioral symptoms). The preparation can be an injection, spray, aerosol, nasal drops, oral preparation, or a dosage form suitable for mucosal administration. In addition, the route of administration to the subject includes, but is not limited to, intramuscular, intravenous, subcutaneous, intradermal, oral, intranasal, respiratory, transmucosal, sublingual, and parenteral.
[0014] The present invention provides that linaloside can promote cholesterol efflux by activating PPARγ-LXRα-ABCA1 / ABCG1 pathway, thereby inhibiting the formation of foam cells and alleviating atherosclerosis. Linaloside is effective in treating atherosclerosis in the field of pharmaceutical technology. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 Zhongyin Tiliaoside alleviates LPS-induced inflammation and oxidative stress. (A) CCK8 detected the toxicity of Zhongyin Tiliaoside on macrophages; (B, C, D) Inflammatory factors IL-6, TNF-α, IL-1β mRNA levels; (E, F, G) ELISA kits detected the concentrations of IL-6, TNF-α, IL-1β in cell supernatants; (H) NO levels; (I, J) ROS levels. Data are expressed as mean ± standard deviation and are from three independent experiments. Statistical significance is as follows: *P<0.05, **P<0.01, ***P<0.001;
[0016] Figure 2 Zhongyin Tiliaoside reduces lipid deposition in foam cells. (A, B) Oil red 0 staining was used to detect lipid accumulation in foam cells. (C, D, E) Enzymatic assay was used to measure the content of intracellular total cholesterol (TC), free cholesterol (FC) and cholesterol ester (CE). Data are expressed as mean ± SD from three independent experiments. Statistical significance is as follows: *P<0.05, **P<0.01, ***P<0.001;
[0017] Figure 3 Zhongyin Tiliaoside inhibits foam cell formation by promoting cholesterol efflux. (A, B, C) The mRNA expression levels of cholesterol uptake-related receptors (including CD36, SR-A, and LOX-1) were evaluated. (D, E) The mRNA levels of cholesterol esterification and hydrolysis enzymes (especially Nceh1 and ACAT-A) were analyzed. (F, G, H) In addition, cholesterol efflux-related transporters (including ABCA1, ABCG1, and SR-Bl) were also evaluated. (1, J) After incubation with Dil-oxLDL for 4 h, the samples were observed by fluorescence microscopy. (K, L, M, N) The effect of Zhongyin Tiliaoside on the protein expression of ABCA1 and ABCG1 was further studied. (0, P) After incubation with apoA-1 or HDL for 6 h, the cholesterol efflux rate was determined by enzyme-linked immunosorbent assay. Data are expressed as mean ± SD and are from three independent experiments. Statistical significance is expressed as *P<0.05, **P<0.01, ***p<0.001;
[0018] Figure 4 Network pharmacology analysis of tilia ginseng for the treatment of atherosclerosis (A) The chemical structure of tilia ginseng is described. (B) The Venn diagram shows the cross-targets of tilia ginseng and AS. (C) The PPI network shows the interaction between tilia ginseng and AS-related proteins. (D) An interaction network highlights the key AS target proteins affected by tilia ginseng. (E) GO functional enrichment analysis of the identified targets. (F) KEGG pathway enrichment analysis reveals the signaling pathways that tilia ginseng may regulate;
[0019] Figure 5PPAR-γ is necessary for tilia glycosides to reduce lipid droplet accumulation in foam cells by promoting cholesterol efflux. (A, B, C) Foam cells were treated with tilia glycosides or 0x-LDL for 24 h, after which the expression levels of PPAR-γ and LXR-α were determined by Western blot analysis. (D, E) The accumulation of intracellular lipid droplets was detected by staining with 10uM Oil Red 0 before treatment with tilia glycosides for 24 h. (F, G, H, I) The protein levels of LXR-α, ABCA1, and ABCG1 in foam cells were evaluated by Western blot analysis. (J, K) Quantification of apoA-1 and HDL-mediated cholesterol efflux. Data are expressed as the mean ± SEM of three independent experiments. Statistical significance is expressed as *P<0.05, **P<0.01, ***P<0.001;
[0020] Figure 6 Zhongyin Tiliaoside alleviates the progression of AS in ApOE- / - mice. (A) The effect of 12 weeks of zhongyin Tiliaoside treatment on the changes in body weight of ApOE- / - mice was evaluated. (BE) The effect of zhongyin Tiliaoside on the serum levels of total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein (HDL) in mice with atherosclerosis was evaluated. (FH) The effect of zhongyin Tiliaoside on the serum levels of inflammatory cytokines IL-1B and IL-6, (I) The aortic arch of mice was photographed to visually evaluate the treatment effect. (JM) Hematoxylin and eosin (HE) staining and oil red 0 staining were performed to determine the size and area of aortic arch plaques, and then the positive staining area was quantitatively analyzed. Data are expressed as mean ± SD and are from three independent experiments. Statistical significance is expressed as *P<0.05, **P<0.01, ***p<0.001, ****p<0.0001;
[0021] Figure 7 The effects of arginine on the expression of PPAR-γ, LXR-α, ABCA1 and ABCG1 in the aorta of Ap0E- / - mice were evaluated in the present study. (AD) Immunofluorescence analysis was performed to evaluate the protein expression of PPAR-γ, LXR-α, ABCA 1 and ABCG 1 in CD68+ cells in aortic sections, and the nuclei were counterstained with agar. The scale bar represents 100 μm. (E) Image J software was used to quantify the fold changes in the double-positive staining areas of PPAR-γ, LXR-α, ABCA1 and ABCG1 relative to CD68, compared with the control group. (FJ) Western blot analysis was performed to determine the protein expression levels and band density of PPAR-γ, LXR-α, ABCA1 and ABCG1 in the aorta. Data are presented as the mean ± SD of three independent experiments. Statistical significance is indicated as *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001;
[0022] Figure 8 Molecular dynamics simulation of PPAR-γ-silver basalside in . (A) Molecular docking module diagram of PPAR-γ and silver basalside. (B) RMSD monitoring value of PPAR-γ-silver basalside during 100ns simulation; (C) RMSF monitoring value of PPAR-γ-silver basalside during 100ns simulation; (D) Statistics of the number of hydrogen bonds in the PPAR-γ-silver basalside complex during 100ns simulation; Free energy landscape of the PPAR-γ-silver basalside complex during 50ns simulation; (F) Binding free energy of the PPAR-γ-silver basalside complex calculated based on the MM-PBSA method; (E) Energy decomposition of residues in the PPAR-γ-silver basalside complex. DETAILED DESCRIPTION
[0023] The following will be combined with the accompanying drawings to clearly and completely describe the technical solutions in some embodiments of the present disclosure. Obviously, the described embodiments are only part of the embodiments of the present disclosure, rather than all the embodiments. Based on the embodiments provided by the present disclosure, all other embodiments obtained by ordinary technicians in this field belong to the scope of protection of the present disclosure.
[0024] The experimental reagents and related experimental drugs used in the experiments of the present invention are as follows:
[0025] Tilia arginosa (Tle, 20316-62-5, HPLC purity ≥98%) was purchased from Chengdu Lemeitian Pharmaceutical Technology Co., Ltd. (Chengdu, China).
[0026] DiI-oxidized low-density lipoprotein (Dil-oxLDL, YB-0010) and oxidized low-density lipoprotein (ox-LDL, YB-002) were from Yiyuan Biotechnology (Guangzhou, China).
[0027] Oil red O staining kit (G1016), mouse interleukin-6 (IL-6) ELISA kit (MM-0163M2), interleukin-1β (IL-1β, MM-0040M1), and tumor necrosis factor-α (TNF-α, MM-0132M1) ELISA kits were purchased from Mayen Technology (Nanjing, China).
[0028] The total cholesterol (TC) detection kit (BC1985) and free cholesterol (FC) detection kit (BC1895) were provided by Beijing Solebow Technology Co., Ltd.
[0029] 1. Animal Experimental Protocol
[0030] ApoE- / - mice (male, 8 weeks old), with C57BL / 6J genetic background, were purchased from Saiye Biotechnology Co., Ltd. (Jiangsu, China). These mice were housed in specific pathogen free (SPF) cages at the Experimental Animal Center of Southwest Medical University. They were housed in an environment with a controlled temperature of 25±1°C and a 12-h day-night cycle, with free access to water throughout the experiment, and were fed a Western diet (21% milk fat, 0.15% cholesterol content, and the rest was normal mouse chow). A total of 48 mice were randomly divided into four groups: control group (normal C57 mice), model group, low-dose tiliaceus glycoside (Tle-L, 50 mg / kg) group, and high-dose tiliaceus glycoside (Tle-H, 100 mg / kg) group. Starting from the fifth week (after the first four weeks of Western diet, and then 12 weeks of administration), the group receiving tiliaceus glycoside treatment was given the corresponding dose twice a week through a gastric tube, while the control group and model group were given an equal volume of 0.5% CMC-Na solution. At the end of week 16, mice were anesthetized with sodium pentobarbital and euthanized. The whole aorta was harvested for histopathological analysis, and blood samples were collected for serological evaluation using commercial kits (TC, TG, HDL, L-LDL detection kits from Nanjing Jiancheng Bioengineering Institute).
[0031] 2. Cell lines and culture conditions
[0032] Mouse macrophage cell line RAW264.7 (collected from the above euthanized mice) was cultured in DMEM (Gibco) containing 10% fetal bovine serum (Gibco) and 1% penicillin-streptomycin (Invitrogen) and cultured in a humidified incubator at 37°C and 5% CO2. Passage was performed when the cell density exceeded 90%. Before the start of the experiment, mouse macrophages were pretreated with tiliroside for 4 hours, and then further treated with oxidized low-density lipoprotein (ox-LDL) or lipopolysaccharide (LPS) for subsequent experiments (i.e., cells were plated one day in advance, and after the cell growth state and density were appropriate, the corresponding concentration of tiliroside was added for intervention. When the tiliroside intervention time reached 4 hours, ox-ldl or LPS was added for treatment).
[0033] Cell viability assay
[0034] Cell viability was assessed by cell counting kit-8 (CCK-8, BD Biotech). After treatment, 100 μL of CCK-8 working solution was added to each well of a 96-well plate and incubated at 37 °C for 2 h. The optical density of each well was then measured at 450 nm using a microplate reader.
[0035] NO detection
[0036] To investigate the nitric oxide (NO) scavenging properties of tiliroside in mouse macrophages, RAW 264.7 cells were stimulated with lipopolysaccharide (LPS, 100 ng / mL) for 24 h to induce NO production. Subsequently, cells were treated with tiliroside before continuing to culture for 24 h (macrophobic cells were first stimulated with LPS for 24 h to produce NO, followed by tiliroside intervention for 24 h), and the culture medium was collected. The NO content in the samples was determined using a kit (BD Biotech, S0021M).
[0037] 3. ROS detection
[0038] The reactive oxygen species (ROS) scavenging activity of argentin was evaluated in 12-well plates. RAW264.7 cells were treated with lipopolysaccharide (LPS, 100 ng / mL) for 24 h to induce the production of intracellular ROS. Subsequently, the cells were pretreated with argentin for 4 h before the addition of the DCFH-DA probe (10 μM) to detect intracellular ROS. After incubation for 30 min, the green fluorescence signal in the cells was observed using a fluorescence microscope.
[0039] 4. RT-PCR
[0040] Total RNA was extracted from samples (including collected macrophage specimens or mouse aortic tissue) using TRIzol reagent (Invitrogen, USA) according to the manufacturer's instructions. Complementary DNA (cDNA) was synthesized using a reverse transcription kit (Vazyme, China), and quantitative polymerase chain reaction (qPCR) was performed using SYBR Green (Vazyme, China). The mRNA expression levels of ABCA1, ABCG1, SR-BI, CD36, LOX-1, SR-A, Nceh1, ACAT-1, TNF-α, IL-6, and IL-1β were quantitatively analyzed. The primers used for qPCR are listed in Supplementary Table 1. All data were normalized to the mRNA expression level of β-actin.
[0041] Table 1
[0042]
[0043] Table1Primer sequencesiused forqRT-PCR
[0044] 5. Cellular uptake of oxLDL
[0045] RAW264.7 cells were first incubated with arginine for 4 hours, and then DiI-labeled oxidized low-density lipoprotein (DiI-oxLDL, 40 μg / mL) was added and incubated for another 4 hours. Afterwards, the cells were washed with phosphate buffered saline (PBS), and the uptake of oxidized low-density lipoprotein (oxLDL) was observed under a fluorescence microscope.
[0046] 6. Oil Red O staining
[0047] The formation of foam cells was analyzed using Oil Red O staining. Briefly, cells were seeded into 12-well plates and treated with oxidized low-density lipoprotein (ox-LDL) or arginine for 24 hours, then washed with PBS, fixed with 4% formaldehyde at room temperature for 10 minutes, and then washed with PBS. Modified Oil Red O staining solution was added and the cells were stained for 20 minutes. The staining solution was then removed and the cells were washed with staining wash solution. Subsequently, images were captured using a microscope and the stained areas were analyzed using ImageJ software.
[0048] The frozen sections of mouse aorta were immersed in modified Oil Red O staining working solution. After staining for 20 minutes, the staining solution was removed and the sections were immersed in staining washing solution for 30 seconds. The sections were then immersed in distilled water and washed on a shaker for 20 seconds. Finally, the sections were observed and photographed under a microscope, and the positive staining area was quantitatively analyzed using ImageJ software.
[0049] Western blotting
[0050] Aorta or macrophages were lysed using RIPA buffer (BD Biotech, China) to extract total protein. Equal amounts of protein were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Billerica, MA, USA). After blocking the membranes with protein-free rapid blocking buffer for 1 h, they were incubated with various specific primary antibodies, followed by incubation with horseradish peroxidase (HRP)-conjugated secondary antibodies.
[0051] 7. Cholesterol efflux experiment
[0052] Mouse macrophages were first treated with argentin for 4 hours, then labeled with 100 μL of cholesterol and incubated in the dark at 37°C for 16 hours. In order to allow cholesterol to flow out to high-density lipoprotein (HDL) or apolipoprotein AI (ApoA-I), the cells were treated with HDL or ApoA-I for 6 hours, respectively. After the treatment, the supernatant was transferred to a new 96-well black plate, and 100 μL of cell lysis solution was added to lyse the remaining cells. The absorbance was measured at Ex / Em=485 / 530nm using an enzyme-linked immunosorbent assay (ELISA). The percentage of cholesterol outflow was calculated as the ratio of the absorbance measured in the supernatant to the sum of the absorbances of the cell lysate and the supernatant.
[0053] 8. Immunofluorescence
[0054] After tissue sections were fixed, antigen retrieval was performed and then blocked with 3% bovine serum albumin (BSA) for 1 hour at room temperature. Then, the sections were incubated with a mixture of CD68 (mouse macrophage marker) and primary antibodies at 4°C overnight. The next day, the sections were incubated with the corresponding secondary antibodies for 50 minutes at room temperature in the dark. The nuclei were counterstained with DAPI and then sealed with anti-fading mounting media. Finally, the sections were observed under a fluorescence microscope, photographed, and quantitatively analyzed using ImageJ software.
[0055] 9. Network Pharmacology
[0056] Potential targets of tilia ginseng were identified using PharmMapper and the Swiss Target Prediction System. After removing duplicates, the remaining targets were normalized using the Universal Protein (UniProt) database to obtain drug-related targets. Similarly, targets associated with atherosclerosis were identified by searching the GeneCards database and the OMIM database using the keyword “atherosclerosis”. These targets were also deduplicated, normalized using the UniProt database, and used to obtain the final atherosclerosis disease targets. Overlapping tilia ginseng-related and atherosclerosis disease targets were determined using the Venny 2.1 online drawing tool to identify common “drug-disease” targets. Protein-protein interaction (PPI) data were retrieved from the STRING v.11.5 database, with the species limited to “Homo sapiens” and the confidence score cutoff set to >0.4. The PPI network was established and visualized using the Cytoscape software. Subsequently, enrichment analysis was performed using Metascape.
[0057] 10. Molecular docking
[0058] The three-dimensional structure of argentea tinctoria was downloaded from PubChem database in structure data file (SDF) format and converted to “mol2” format using OpenBabel 3.1.1 software. Then, the structure was prepared for docking using AutoDockTools by adding hydrogen atoms, setting as ligands, determining torsion centers, and selecting rotatable bonds, and then exported to PDBQT format. The target protein structure was obtained from the Protein Data Bank (PDB) database. Human proteins with one or more co-crystallized ligands and high-resolution crystal structures were selected, saved in PDB format, hydrogen atoms were removed using AutoDockTools, set as receptors, and exported to PDBQT format. GridBox parameters were adjusted using AutoDock4.2.6 software until the box contained all receptor molecules. Blind docking was performed to identify active sites, and a grid point parameter file (GPF) was exported. Docking parameters and algorithms were set, and docking was performed using AutoDock4. Then, the results were visualized using PyMOL2.4.0 software. Finally, to obtain docking scores, proteins and compounds were uploaded to DockThor for online molecular docking.
[0059] Molecular dynamics simulation
[0060] 11. Molecular dynamics simulations were performed using Gromacs 2022.3 software. Small molecule pretreatment involved applying the General Amber Force Field (GAFF) using AmberTools22 and Gaussian 16W to hydrogenate the molecules and calculate the restricted electrostatic potential (RESP). The generated potential energy data were integrated into the topology file of the molecular dynamics system. The simulations were performed at a constant temperature of 300K and atmospheric pressure (1 bar). The Amber99SB-ILDN force field was used to simulate water molecules with the TIP3P water model as the solvent, and the appropriate amount of Na + ions to neutralize the overall charge of the system. Energy minimization was performed using the steepest descent method, followed by 100,000 steps of equilibration under the isothermal-isochroic ensemble (NVT) and the isothermal-isobaric ensemble (NPT), respectively, with a coupling constant of 0.1 ps and a duration of 100 ps. The final molecular dynamics simulation involved 5 million steps with a time step of 2 femtoseconds and a total of 100 nanoseconds. Upon completion, the simulation trajectories were analyzed using built-in tools to calculate the root mean square deviation (RMSD), root mean square fluctuation (RMSF) and radius of rotation for each amino acid trajectory, as well as free energy (MMGBSA) and free energy landscape data.
[0061] pass Figure 1It is known that atherosclerotic plaques are characterized by the significant presence of activated macrophages, which promote the development of atherosclerosis by secreting proinflammatory cytokines and inducing oxidative stress. The CCK-8 experiment was used to evaluate the effect of linaloside on cell activity. The results showed that at concentrations of 10μM, 20μM and 40μM, linaloside did not significantly affect cell activity, maintaining activity above 80% ( Figure 1 A). Therefore, these concentrations were selected for subsequent experiments. Lipopolysaccharide (LPS) induces macrophage activation, which is manifested by increased levels of inflammatory factors, nitric oxide (NO), and reactive oxygen species (ROS). We investigated the effects of tilia glycosides on inflammation and oxidative stress in RAW264.7 macrophages. As expected, LPS-activated macrophages showed significantly increased IL-6, TNF-α, and IL-1β mRNA expression, which were significantly reduced by tilia glycosides treatment ( Figure 1 In addition, ELISA analysis showed that the expression levels of IL-6, TNF-α, and IL-1β in the cell culture supernatant treated with LPS were significantly increased, while the intervention with linaloside significantly reduced the levels of these inflammatory factors ( Figure 1 E, F, G). In addition, tilia glycoside treatment effectively inhibited the production of NO in activated macrophages ( Figure 1 H). LPS-activated macrophages exhibited high levels of ROS, as indicated by the strong green fluorescence emitted by DCFH-DA. After intervention with linaloside, the intracellular fluorescence intensity was significantly reduced, reflecting its effect on ROS scavenging ( Figure 1 I, J). These results suggest that arginine can inhibit macrophage activation and has potential anti-atherosclerotic properties.
[0062] pass Figure 2 It is known that in the early stages of atherosclerosis (AS), macrophages take up oxidized low-density lipoprotein (ox-LDL) through scavenger receptors to form foam cells, which is considered to be a hallmark of atherosclerotic lesions. The continued presence of cholesterol-filled foam cells in the arterial wall accelerates the progression of AS. In order to confirm the inhibitory effect of linaloside on foam cell formation, we established a foam cell model using RAW 264.7 macrophages. Oil red O staining results showed that compared with the control group, the lipid droplets in the model group macrophages increased significantly after ox-LDL (60 μg / mL) treatment for 24 hours, confirming the successful establishment of the foam cell model. After treatment with different concentrations of linaloside, the accumulation of lipid droplets in foam cells was significantly reduced in a dose-dependent manner ( Figure 2A, B). Intracellular cholesterol analysis showed that ox-LDL treatment significantly increased the levels of total cholesterol (TC), free cholesterol (FC), and cholesterol ester (CE) in foam cells compared with the control group. Notably, pretreatment with arginine significantly reduced the levels of TC, FC, and CE in foam cells in a dose-dependent manner ( Figure 2 C, D, E). These results indicate that arginine inhibits the formation of macrophage foam cells.
[0063] pass Figure 3 It can be seen that the formation of foam cells is mainly due to the imbalance of three biological processes: cholesterol uptake, esterification and efflux. Macrophages take up ox-LDL through several scavenger receptors, including CD36, SR-A and LOX-1. RT-qPCR results showed that after ox-LDL treatment, the mRNA expression of CD36, SR-A and LOX-1 in macrophages increased significantly, indicating that the ability of macrophages to take up cholesterol was enhanced. However, compared with the model group, treatment with different concentrations of linalool did not reduce the mRNA expression levels of CD36, SR-A and LOX-1 ( Figure 3 A, B, C). In addition, we evaluated the gene expression of enzymes involved in cholesterol esterification and hydrolysis. Similarly, compared with the model group, arginine intervention had no significant effect on the expression of Nceh1 and ACAT-1 genes in foam cells ( Figure 3 D, E). These results indicate that tilia glycosides had no effect on the mRNA levels associated with cholesterol uptake or esterification in macrophages. We then examined the effect of tilia glycosides on the mRNA expression of ABCA1, ABCG1, and SR-BI, which are involved in cholesterol efflux. Unexpectedly, 40 μM tilia glycosides significantly upregulated the mRNA expression of ABCA1 and ABCG1, but had no effect on the mRNA level of SR-BI compared with the model group ( Figure 3 F, G, H). DiI-oxLDL was used to observe the effect of tilia glycosides on cholesterol uptake. The results showed that after treatment with tilia glycosides, the red fluorescence signal in macrophages did not change significantly, further confirming that tilia glycosides did not affect the uptake of cholesterol by macrophages ( Figure 3 I, J). Previous studies have shown that ABCA1 and ABCG1 are essential for macrophages to clear excess intracellular cholesterol, contributing to the prevention and reversal of atherosclerosis. Enhancing cholesterol efflux through ABCA1 and ABCG1 is expected to prevent the progression of atherosclerosis. Western blot analysis showed that arginine treatment significantly upregulated the protein expression of ABCA1 and ABCG1 in foam cells ( Figure 3K, L, M, N). As key proteins in the reverse cholesterol transport process, ABCA1 and ABCG1 are responsible for transporting excess intracellular free cholesterol to ApoA-I and mature high-density lipoprotein (HDL) particles, respectively, and therefore play a vital role in maintaining intracellular cholesterol homeostasis and preventing foam cell formation. Therefore, we evaluated the effect of linaloside on cholesterol efflux using a cholesterol efflux assay kit. The results showed that in macrophages, linaloside enhanced the transport of intracellular cholesterol to HDL ( Figure 3 O) and ApoA-I( Figure 3 Collectively, these findings suggest that arginine inhibits foam cell formation by increasing cholesterol efflux mediated by ABCA1 and ABCG1.
[0064] pass Figure 4 It is known that network pharmacology is an emerging discipline that applies systems biology, network analysis, and multidimensional data integration techniques to drug research. Its core concept is to systematically analyze the interaction between drugs and biological systems by constructing complex networks between drugs, targets, diseases, and biological pathways. This approach aims to reveal the mechanism of action, potential side effects, and potential of multi-target therapy of drugs. In order to further clarify the potential targets of linaloside in the treatment of atherosclerosis, network pharmacology analysis was performed.
[0065] like Figure 4 As shown in A, the chemical structure of tilia glycosides was retrieved from the PubChem database and subsequently imported into the PharmMapper database. After correcting and standardizing the target names using the UniProt database, 100 targets were identified. Targets associated with atherosclerosis were compiled from the GeneCards, OMIM, and TTD databases. After removing duplicates and integrating the data, a total of 4920 targets associated with atherosclerosis were identified. The 100 tilia glycoside targets were cross-referenced with the 4920 atherosclerosis targets, and 69 common targets that may improve atherosclerosis through tilia glycosides were found ( Figure 4 B). These anti-atherosclerotic targets were then processed using the STRING database to construct a protein-protein interaction (PPI) network diagram ( Figure 4 C). The network topology analysis was further performed using Cytoscape 3.9.1 software, and the five core targets with the highest centrality were identified, namely TNF, TP53, PPARG, MTOR, and HSP90AA1 ( Figure 4D). Subsequently, GO enrichment analysis of therapeutic targets at different levels was performed using the DAVID database. The results are presented as a bar graph, highlighting the top 10 enriched terms with the highest gene counts in biological process (BP), cellular composition (CC), and molecular function (MF). The results showed that BP terms were mainly related to signal transduction, negative regulation of apoptotic processes, and proteolysis. CC terms were mainly concentrated in the cytoplasm, extracellular regions, and extracellular exosomes. MF terms were mainly involved in same protein binding, zinc ion binding, and enzyme binding ( Figure 4 E). In order to systematically study the potential mechanism of linaloside against atherosclerosis, the KEGG pathway was used to predict the related anti-atherosclerosis signaling pathways of linaloside. The top 10 pathways ranked by the number of related genes are shown in a bar graph, and "cancer pathway", "PI3K-Akt signaling pathway" and "lipid and atherosclerosis" become the top three pathways ( Figure 4 F).
[0066] pass Figure 5 It can be seen that previous studies have shown that the PPARγ-LXRα-ABCA1 / ABCG1 pathway plays an important role in regulating cholesterol efflux. LXRα is crucial in the transcriptional activation of ABCA1 and ABCG1, and PPARγ serves as an upstream regulator of LXRα. Studies have shown that tilia glycosides may activate PPARs and participate in the regulation of glucose and lipid metabolism, thereby contributing to the management of diseases such as diabetes and metabolic syndrome. In addition, the results of network pharmacology analysis also showed that the anti-atherosclerotic effect of tilia glycosides is closely related to the regulation of PPARγ and lipid metabolism. Taken together, PPARγ may be a potential target for tilia glycosides to exert their anti-atherosclerotic effects, which prompted us to choose PPARγ for experimental verification. Western blotting results showed that tilia glycoside treatment significantly upregulated the protein expression of PPARγ and LXRα in foam cells, consistent with our hypothesis ( Figure 5 A, B, C). To further elucidate the effect of PPARγ on the promotion of cholesterol efflux and inhibition of foam cell formation induced by tilia glycosides, we used a specific PPARγ inhibitor, T0070907. Notably, we observed that inhibition of PPARγ reversed the reduction of lipid droplets induced by tilia glycosides treatment in foam cells ( Figure 5 D, E). In addition, silencing PPARγ reversed the upregulation of LXRα, ABCA1, and ABCG1 protein expressions induced by tilia ginsenoside ( Figure 5 F, G, H, I). In contrast, administration of the PPARγ antagonist T0070907 counteracted the enhanced cholesterol efflux to apoA-I and HDL induced by arginine ( Figure 5J, K). These results suggest that arginine promotes cholesterol efflux by upregulating the expression of LXRα, ABCA1, and ABCG1, thereby inhibiting the formation of foam cells in a PPARγ-dependent manner.
[0067] pass Figure 6 It is known that the effect of linaloside (Tle) on atherosclerotic plaque formation was evaluated using ApoE- / - mice as an animal model of atherosclerosis (AS). Initially, we evaluated the weight difference between the model group and the group treated with linaloside for 12 weeks and found no statistically significant difference ( Figure 6 A). We then measured blood lipid levels and observed that serum total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) levels increased in the model group compared with the control group, but were significantly decreased after argyroside treatment ( Figure 6 B, C, D). In addition, the serum high-density lipoprotein cholesterol (HDL-C) level in the model group was reduced compared with the control group, and this phenomenon was reversed by the treatment with linaloside ( Figure 6 E). We also examined the changes in serum inflammatory factors and found that IL-6, TNF-α, and IL-1β were significantly increased in the model group compared with the control group. However, compared with the model group, linaloside treatment significantly reduced the levels of these inflammatory markers ( Figure 6 F, G, H). At the same time, we evaluated the effect of linaloside on aortic plaque formation in ApoE- / - mice. Photos of the aortic arch showed that a large number of atherosclerotic plaques were formed in the model group compared with the control group, while linaloside treatment significantly reduced plaque formation in this area ( Figure 6 I). In addition, histological examination of the aortic root showed that the plaques in the model group worsened, as shown by hematoxylin and eosin (H&E) and Oil Red O staining, but the plaque area was significantly reduced after arginine treatment ( Figure 6 J, K, L, M). These results suggest that arginine can improve lipid profiles, reduce inflammation, and attenuate atherosclerotic plaque formation in ApoE- / - mice.
[0068] Studies have shown that individuals carrying ABCA1 gene mutations are more likely to have low levels of high-density lipoprotein (HDL) and significantly increased risk of atherosclerosis. This finding emphasizes the key role of ABCA1 in maintaining intravascular cholesterol homeostasis and preventing atherosclerosis. In addition, the loss of ABCG1 significantly promotes the formation of atherosclerotic plaques in the ApoE- / - mouse model, further establishing the core role of ABCG1 in inhibiting atherosclerosis.
[0069] pass Figure 7It can be seen that in order to further study the effect of linaloside on the expression of PPARγ, LXRα, ABCA1 and ABCG1 in aortic macrophages, we used CD68 antibody to perform double immunofluorescence staining on macrophages. Colocalization analysis showed that the expression of PPARγ, LXRα, ABCA1 and ABCG1 in plaque macrophages was significantly upregulated in the Tle group compared with the model group ( Figure 7 A, B, C, D). This upregulation was confirmed to be statistically significant ( Figure 7 E). In addition, Western blot analysis showed that arginine significantly increased the protein levels of PPARγ, LXRα, ABCA1, and ABCG1 in aortic tissues of ApoE- / - mice ( Figure 7 FJ). Overall, these findings suggest that arginine may promote cholesterol efflux through activating PPARγ, thereby alleviating atherosclerosis in mice.
[0070] pass Figure 8 It is known that molecular docking is a computational technology that simulates the binding mode of drug molecules with biological targets (such as protein receptors), identifies potential drug targets and verifies their interactions with drugs, thereby revealing the molecular mechanism of drugs. Molecular dynamics simulation studies the dynamic behavior of molecular systems by simulating the motion trajectories of molecules and atoms. By evaluating the long-term interaction between drugs and targets, this technology evaluates the stability and kinetic behavior of binding, providing a theoretical basis for predicting in vivo drug performance and potential side effects. These technologies play a vital role in drug design and disease mechanism research, accelerating the development of new drugs and improving the accuracy and effectiveness of treatment.
[0071] In order to further clarify the binding mechanism of tilia glycosides with PPARγ, we used molecular docking and molecular dynamics simulation. The molecular docking results showed that tilia glycosides exhibited a strong binding affinity with PPARγ, and its binding free energy was -7.5kcal / mol ( Figure 8 A). The interaction between arginine and PPARγ involves key amino acid residues, including LEU-340, ARG-288, ALA-292, TYR-327, and TYR-473. The root mean square deviation (RMSD) was used to evaluate the internal structural changes of the protein, showing that during the 100 nanosecond simulation, the PPARγ-arginine complex reached equilibrium at 18 nanoseconds, and the RMSD value remained in a narrow range, indicating a stable binding ( Figure 8 B). In addition, root mean square fluctuation (RMSF) analysis showed that the fluctuation value was lower in the bound area and higher in the unbound area, indicating that PPARγ-silver linaloside binding enhanced the stability of the protein ( Figure 8C). Throughout the simulation, the number of hydrogen bonds (HBond) between PPARγ and arginine was high, especially the strong interactions between key residues and key groups of small molecules ( Figure 8 D). The free energy landscape (FEL) constructed using RMSD, radius rotation (Rg), and Gibbs free energy showed that the complex maintained Rg values between 2.54 and 2.67 nm and RMSD values between 0.20 and 0.39 nm, recording the lowest energy state ( Figure 8 E). These minimum energy values indicate that the complex exhibits a highly stable structure throughout the simulation. Using the MM-PBSA method to calculate the binding free energy of the last 5 nanoseconds of the simulation, it was found that van der Waals interactions, electrostatic interactions, nonpolar solubility energy, and molecular mechanics energy all favored the binding affinity, indicating a strong interaction between PPARγ and arginine ( Figure 8 F). Further analysis of the energy contributions of individual residues identified ILE-326, GLU-295, and ALA-292 as the major contributors to the total binding energy ( Figure 8 G). Taken together, these results indicate that the PPARγ-arginine interaction is characterized by favorable binding properties and stability, as evidenced by the overall structural integrity, compactness, and interaction strength during the 100 ns simulations.
[0072] In the description of this specification, specific features, structures, materials or characteristics may be combined in an appropriate manner in any one or more embodiments or examples.
[0073] The above is only a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any person skilled in the art can easily think of changes or substitutions within the technical scope disclosed by the present invention, which should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.
Claims
1. Application of linalool in the preparation of drugs for the treatment of atherosclerosis.
2. The use according to claim 1, characterized in that: The structural formula of the linalool is:
3. The use according to claim 1, characterized in that: The daily dosage of the linaloside is 500 mg.
4. The use according to claim 1, characterized in that: The drug is administered by injection or orally.
5. The use according to claim 1, characterized in that: The medicine comprises a medicine preparation prepared by taking an effective amount of linalool as an active ingredient and adding a pharmaceutically acceptable carrier and / or auxiliary material.
Citation Information
Patent Citations
Composition for preventing, ameliorating or treating metabolic syndrome
EP2815756A1
